Aleksandr L. Muzurov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Aleksandr L. Muzurov has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Galina A. Generalova
Center of Gravitational Blood Surgery and Hemodialysis of Saint Vladimir Children’s Clinical Hospital; Russian Medical Academy of Continuing Professional Education
7 shared publications - Khadizha M. Emirova
A.I. Yevdokimov Moscow State University of Medicine and Dentistry; Children’s State Clinical Hospital of St. Vladimir
7 shared publications - Tatiana E. Pankratenko
Center of Gravitational Blood Surgery and Hemodialysis of Saint Vladimir Children’s Clinical Hospital
6 shared publications - Tatiana Yu. Abaseeva
Russian University of medicine, Ministry of Health of the Russian Federation; G.N. Speransky Children’s City Clinical Hospital No.9; Children’s State Hospital of St. Vladimir, Moscow Healthcare Department
6 shared publications Moscow Russian Medical Academy For Continuous Professional Education
5 shared publications- Olga M. Orlova
Department of Pediatrics, A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Moscow 127473, Russia
5 shared publications
Latest Publications
- Open Access
- 26 December 2025
- Published by ECO-Vector LLC (Publications) in Russian Journal of Pediatric Surgery, Anesthesia and Intensive Care
- Vol. 15 (4) , 583-619
2025 national clinical huideline for sepsis in children
This article is an adapted version of the federal clinical guidelines on sepsis in children, developed by the specialists of the Association of Pediatric Anesthesiologists and Intensivists of Russia and approved by the Ministry of Health of the Russian Federation on October 10, 2025. Definitions of sepsis and septic shock in pediatric patients are substantiated, including their criteria. Data on etiology and pathogenesis, epidemiology, clinical presentation, and diagnosis of shock are presented. Recommendations for intensive care management of sepsis and septic shock include sections on antimicrobial therapy in pediatric sepsis, hemodynamic, respiratory, and nutritional support, renal replacement therapy and extracorporeal blood purification, and adjuvant therapy. It also discusses controversial issues related to the use of immunomodulatory agents, corticosteroids, and vitamins. The work emphasizes that in children with septic shock, antimicrobial therapy should be initiated no later than 1 hour after diagnosis, whereas in the absence of shock it should be started no later than 3 hours after diagnosis. It is noted that infusion therapy in children with septic shock during the first hour after diagnosis should not exceed 40 mL/kg in order to prevent fluid overload, with balanced crystalloid electrolyte solutions recommended as first-line agents for volume resuscitation. In septic shock, norepinephrine and epinephrine are the drugs of choice for hemodynamic correction, whereas dopamine is not recommended. It is demonstrated that septic shock and severe acute respiratory distress syndrome are absolute indications for invasive mechanical ventilation using lung-protective strategies. The importance of early initiation of enteral nutrition in children with sepsis and septic shock is emphasized; it is considered justified even during infusion of inotropic agents provided that hemodynamic parameters are stable. Renal replacement therapy is indicated not only for substitution of renal function but also for correction of fluid overload when diuretic therapy is ineffective. Convincing evidence is presented that the use of plasma exchange and sorption techniques in children with sepsis and septic shock is currently not recommended. It is noted that hydrocortisone therapy in children with sepsis is justified only in refractory septic shock. Modern principles of metabolic management in sepsis are described, indicating that optimal blood glucose levels in children should not exceed 7.8 mmol/L; insulin therapy is justified when blood glucose levels exceed 10 mmol/L. Data on rehabilitation, prevention, and organization of medical care for pediatric sepsis are also provided.
- 26 December 2025
- Published by ECO-Vector LLC (Publications) in Russian Journal of Pediatric Surgery, Anesthesia and Intensive Care
- Vol. 15 (4) , 583-619
Open Access2025 national clinical huideline for sepsis in children
This article is an adapted version of the federal clinical guidelines on sepsis in children, developed by the specialists of the Association of Pediatric Anesthesiologists and Intensivists of Russia and approved by the Ministry of Health of the Russian Federation on October 10, 2025. Definitions of sepsis and septic shock in pediatric patients are substantiated, including their criteria. Data on etiology and pathogenesis, epidemiology, clinical presentation, and diagnosis of shock are presented. Recommendations for intensive care management of sepsis and septic shock include sections on antimicrobial therapy in pediatric sepsis, hemodynamic, respiratory, and nutritional support, renal replacement therapy and extracorporeal blood purification, and adjuvant therapy. It also discusses controversial issues related to the use of immunomodulatory agents, corticosteroids, and vitamins. The work emphasizes that in children with septic shock, antimicrobial therapy should be initiated no later than 1 hour after diagnosis, whereas in the absence of shock it should be started no later than 3 hours after diagnosis. It is noted that infusion therapy in children with septic shock during the first hour after diagnosis should not exceed 40 mL/kg in order to prevent fluid overload, with balanced crystalloid electrolyte solutions recommended as first-line agents for volume resuscitation. In septic shock, norepinephrine and epinephrine are the drugs of choice for hemodynamic correction, whereas dopamine is not recommended. It is demonstrated that septic shock and severe acute respiratory distress syndrome are absolute indications for invasive mechanical ventilation using lung-protective strategies. The importance of early initiation of enteral nutrition in children with sepsis and septic shock is emphasized; it is considered justified even during infusion of inotropic agents provided that hemodynamic parameters are stable. Renal replacement therapy is indicated not only for substitution of renal function but also for correction of fluid overload when diuretic therapy is ineffective. Convincing evidence is presented that the use of plasma exchange and sorption techniques in children with sepsis and septic shock is currently not recommended. It is noted that hydrocortisone therapy in children with sepsis is justified only in refractory septic shock. Modern principles of metabolic management in sepsis are described, indicating that optimal blood glucose levels in children should not exceed 7.8 mmol/L; insulin therapy is justified when blood glucose levels exceed 10 mmol/L. Data on rehabilitation, prevention, and organization of medical care for pediatric sepsis are also provided.
- Open Access
- 22 April 2025
- Published by Central Research Institute of Radiation Diagnostics in Radiology - Practice
- No. 2,p. 10-27
Ultrasound Support of Peritoneal Dialysis in Children
Background. Treatment of patients with acute kidney injury and chronic kidney disease requires renal replacement therapy, peritoneal dialysis (PD) is one of the methods.Objective. Study of ultrasound capabilities in visualization of PD complications in children.Materials and Methods. Over the last 10 years in the Department of Gravitational Blood Surgery and Hemodialysis of St. Vladimir's Hospital in Moscow, about 605 patients with acute kidney injury and chronic kidney disease aged from 1 month to 17 years 11 months receiving PD treatment were observed, half of them had complaints associated with PD and requiring echographic differential diagnosis. Ultrasound was performed on Acuson/Sequoia 512, Voluson E-8, Voluson E-10, Acuson NX3.Results. The variants of peritoneal catheter (PC) visualization in normal and obstructed conditions were studied: omentum fragments, fat suspensions of the colon and uterine appendages fragments (fimbriae) were visualized as irregularly shaped echogenic inclusions inside the catheter. Dialysis peritonitis in the debut of the disease at ultrasound looked like a finely dispersed suspension in the dialysate, later there was organization of dialysate with the formation of a grid of organized fluid. The possibilities of echographic diagnosis of intestinal obstruction due to PD are analyzed, rare cases of visualization of encapsulating peritoneal fibrosis in children are presented. The possibilities of ultrasound in the assessment of scrotal complications of PD in infants, variants of visualization of ventral hernias are shown. Such rare complications of PD in children as tunnel and hemorrhagic complications are presented.Conclusion Abdominal ultrasound with targeted PC's imaging should be performed on a patient on PD immediately if any abdominal pathology is Changes in the consistency of dialysate on ultrasound in PD allow us to judge the dynamics of the disease and predict the prospects of resumption of PC disruption and dislocation in children can be accurately assessed echographically Intestinal obstruction in children on PD, may be due to PC position, but it is rarely possible to visualize this on In the vast majority of cases, nonspecific changes typical of low bowel obstruction are visualized. If children have hernias provoked by PD, ultrasound can reliably assess the size of the hernia’s sac or dialysate accumulation, visualize the size of the hernia gate and differentiate hernial
- 22 April 2025
- Published by Central Research Institute of Radiation Diagnostics in Radiology - Practice
- No. 2,p. 10-27
Open AccessUltrasound Support of Peritoneal Dialysis in Children
Background. Treatment of patients with acute kidney injury and chronic kidney disease requires renal replacement therapy, peritoneal dialysis (PD) is one of the methods.Objective. Study of ultrasound capabilities in visualization of PD complications in children.Materials and Methods. Over the last 10 years in the Department of Gravitational Blood Surgery and Hemodialysis of St. Vladimir's Hospital in Moscow, about 605 patients with acute kidney injury and chronic kidney disease aged from 1 month to 17 years 11 months receiving PD treatment were observed, half of them had complaints associated with PD and requiring echographic differential diagnosis. Ultrasound was performed on Acuson/Sequoia 512, Voluson E-8, Voluson E-10, Acuson NX3.Results. The variants of peritoneal catheter (PC) visualization in normal and obstructed conditions were studied: omentum fragments, fat suspensions of the colon and uterine appendages fragments (fimbriae) were visualized as irregularly shaped echogenic inclusions inside the catheter. Dialysis peritonitis in the debut of the disease at ultrasound looked like a finely dispersed suspension in the dialysate, later there was organization of dialysate with the formation of a grid of organized fluid. The possibilities of echographic diagnosis of intestinal obstruction due to PD are analyzed, rare cases of visualization of encapsulating peritoneal fibrosis in children are presented. The possibilities of ultrasound in the assessment of scrotal complications of PD in infants, variants of visualization of ventral hernias are shown. Such rare complications of PD in children as tunnel and hemorrhagic complications are presented.Conclusion Abdominal ultrasound with targeted PC's imaging should be performed on a patient on PD immediately if any abdominal pathology is Changes in the consistency of dialysate on ultrasound in PD allow us to judge the dynamics of the disease and predict the prospects of resumption of PC disruption and dislocation in children can be accurately assessed echographically Intestinal obstruction in children on PD, may be due to PC position, but it is rarely possible to visualize this on In the vast majority of cases, nonspecific changes typical of low bowel obstruction are visualized. If children have hernias provoked by PD, ultrasound can reliably assess the size of the hernia’s sac or dialysate accumulation, visualize the size of the hernia gate and differentiate hernial
- 9 August 2024
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 103 (4)
GENETIC AND PHENOTYPIC PROFILE OF PEDIATRIC PATIENTS WITH ATYPICAL HEMOLYTIC-UREMIC SYNDROME
Atypical hemolytic uremic syndrome (aHUS) is a life-threatening disease caused by dysregulation of the alternative complement pathway as a result of mutations in complement genes or the formation of antibodies (AB) to some of the complement factors. Identification of the gene mutations incidence and the corresponding phenotypic features in pediatric patients with aHUS in Russia is aimed at improving the diagnosis and prognosis of the disease as well as treatment tactics planning for patient management. The purpose of this research was to determine the patterns of progression, prognosis and outcomes of aHUS in children depending on their genetic profile. Materials and methods used: the Article represents data from a retro- and prospective analyses of the characteristics of the course of aHUS in 172 children depending on their genetic profile performed in Jan. 2012-Feb. 2022. The sporadic form of aHUS was diagnosed after exclusion of the other forms of thrombotic microangiopathy (TMA), the familial form (in cases with the familial records), the acquired (CFH-Ab HUS) in cases with AB increase to factor H. AutoAb against factor H was determined by enzyme-linked immunosorbent assay (ELISA-VIDITEST anti-complement factor H). The search for mutations (n=167) was carried out using Next-generation Sequencing (NGS) and Sanger sequencing methods. Results: the sporadic form of aHUS was diagnosed in 96.9% of cases, familial in 3.1% and CFH-Ab HUS in 23.8%. The genetic nature of aHUS was confirmed in 53.4% of cases. Pathogenic mutations were detected in 8.6% of cases, probably pathogenic in 42.8% and those with unclear clinical significance in 46.8%. The complement genes mutations were detected in 88.5% of cases and mutations of genes not related to the complement system (ADAMTS13, DGKE, INF2) in 11.5%. The most frequently identified mutations were in the CFH (17.1%), C3 (12.9%) and CD46 (12.9%) genes and less frequently in CFI (7.1%), THBD (5.7%), CFHR5 (5.7%) and CFB (1.4%). In children with CFH-Ab HUS, the CFHR1/CFHR3 deletion was detected in 87.8% of cases, including in 19.4% in combination with mutations of unknown clinical significance. Multiple organ failure syndrome had developed in 77.8% of cases in children with pathogenic/probably pathogenic mutations, in 85.3% in patients with mutations of unknown clinical significance, in 91.8% in patients without mutations and in 83.3% in patients with CFHR1/CFHR3 deletion. Chronic kidney disease (CKD) stages 3 to 5 in sporadic/familial aHUS, regardless of genetic profile, had counted for 14.5% and 16.7% in CFH-Ab HUS. Lethal outcome occurred in 4.3% of cases in the presence of mutations, in 4.9% in the absence of mutations and in 2.8% in cases of CFHR1/CFHR3 deletion. Relapses of aHUS prior to the Eculizumab treatment had developed more often in the presence of CFHR1/CFHR3 mutations and deletion in comparison with children without mutations (31.4% v. 13.1%, p=0.0313 and 44.4% v. 13.1%, p= 0.004). Relapse of aHUS after discontinuation of the Eculizumab therapy had developed in 16.4% of cases. Risk factors for the relapse of aHUS were as follows: patient’s age above 12 months old at the time of the development of aHUS, severe arterial hypertension in the acute period, the use of Eculizumab at the fourth week after the onset of the disease and/or later, recurrent course of aHUS and the presence of CKD prior to the start of the Eculizumab therapy. Conclusion: The genetic profile of patients does not determine the severity and outcome of aHUS though it does affect the relapse rate. The prognosis and survival of patients with aHUS are determined by the severity of the acute period and the timeliness of the complement blocking therapy management.
- 9 August 2024
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 103 (4)
GENETIC AND PHENOTYPIC PROFILE OF PEDIATRIC PATIENTS WITH ATYPICAL HEMOLYTIC-UREMIC SYNDROME
Atypical hemolytic uremic syndrome (aHUS) is a life-threatening disease caused by dysregulation of the alternative complement pathway as a result of mutations in complement genes or the formation of antibodies (AB) to some of the complement factors. Identification of the gene mutations incidence and the corresponding phenotypic features in pediatric patients with aHUS in Russia is aimed at improving the diagnosis and prognosis of the disease as well as treatment tactics planning for patient management. The purpose of this research was to determine the patterns of progression, prognosis and outcomes of aHUS in children depending on their genetic profile. Materials and methods used: the Article represents data from a retro- and prospective analyses of the characteristics of the course of aHUS in 172 children depending on their genetic profile performed in Jan. 2012-Feb. 2022. The sporadic form of aHUS was diagnosed after exclusion of the other forms of thrombotic microangiopathy (TMA), the familial form (in cases with the familial records), the acquired (CFH-Ab HUS) in cases with AB increase to factor H. AutoAb against factor H was determined by enzyme-linked immunosorbent assay (ELISA-VIDITEST anti-complement factor H). The search for mutations (n=167) was carried out using Next-generation Sequencing (NGS) and Sanger sequencing methods. Results: the sporadic form of aHUS was diagnosed in 96.9% of cases, familial in 3.1% and CFH-Ab HUS in 23.8%. The genetic nature of aHUS was confirmed in 53.4% of cases. Pathogenic mutations were detected in 8.6% of cases, probably pathogenic in 42.8% and those with unclear clinical significance in 46.8%. The complement genes mutations were detected in 88.5% of cases and mutations of genes not related to the complement system (ADAMTS13, DGKE, INF2) in 11.5%. The most frequently identified mutations were in the CFH (17.1%), C3 (12.9%) and CD46 (12.9%) genes and less frequently in CFI (7.1%), THBD (5.7%), CFHR5 (5.7%) and CFB (1.4%). In children with CFH-Ab HUS, the CFHR1/CFHR3 deletion was detected in 87.8% of cases, including in 19.4% in combination with mutations of unknown clinical significance. Multiple organ failure syndrome had developed in 77.8% of cases in children with pathogenic/probably pathogenic mutations, in 85.3% in patients with mutations of unknown clinical significance, in 91.8% in patients without mutations and in 83.3% in patients with CFHR1/CFHR3 deletion. Chronic kidney disease (CKD) stages 3 to 5 in sporadic/familial aHUS, regardless of genetic profile, had counted for 14.5% and 16.7% in CFH-Ab HUS. Lethal outcome occurred in 4.3% of cases in the presence of mutations, in 4.9% in the absence of mutations and in 2.8% in cases of CFHR1/CFHR3 deletion. Relapses of aHUS prior to the Eculizumab treatment had developed more often in the presence of CFHR1/CFHR3 mutations and deletion in comparison with children without mutations (31.4% v. 13.1%, p=0.0313 and 44.4% v. 13.1%, p= 0.004). Relapse of aHUS after discontinuation of the Eculizumab therapy had developed in 16.4% of cases. Risk factors for the relapse of aHUS were as follows: patient’s age above 12 months old at the time of the development of aHUS, severe arterial hypertension in the acute period, the use of Eculizumab at the fourth week after the onset of the disease and/or later, recurrent course of aHUS and the presence of CKD prior to the start of the Eculizumab therapy. Conclusion: The genetic profile of patients does not determine the severity and outcome of aHUS though it does affect the relapse rate. The prognosis and survival of patients with aHUS are determined by the severity of the acute period and the timeliness of the complement blocking therapy management.
- 22 February 2024
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 103 (1)
Atypical hemolytic-uremic syndrome associated with antibodies to factor H
Atypical hemolytic-uremic syndrome (aHUS) is an ultra-rare life-threatening disease from the group of thrombotic microangiopathies (TMA) with genetic predisposition factors associated with uncontrolled activation of the alternative complement pathway. In 10% of cases aHUS is acquired and associated with antibodies to factor H (CFH-Ab-aHUS), among which 90% of cases are also determined by a deficiency of plasma proteins related to factor H (CFHR). Information on the course, therapeutic approaches and outcomes of CFH-Ab-aHUS varies Worldwide and is presented by series of clinical observations. The purpose of the research was to determine the patterns of the course and outcomes of CFH-Ab-aHUS to substantiate methods of effective treatment and improve prognosis. Methods used: retro- and prospective analysis of the course and outcomes of CFH-Ab-aHUS in 43 patients in Jan. 2010-Feb. 2022. The sample is continuous. In the development of microangiopathic hemolytic anemia (MAHA), thrombocytopenia and acute kidney injury (AKI), the diagnosis of CFH-Ab-aHUS was established after exclusion of other forms of TMAs and determination of immunoglobulin class G (IgG) in serum against factor H by enzyme-linked immunosorbent assay (ELISA-VIDITEST anti-complement factor H, Czech Republic). In 41 cases molecular genetic study by NGS (next generation sequencing) for aHUS panel and Sanger sequencing were performed. Results: the incidence of CFH-Ab-aHUS was 20.6% among all cases of aHUS. In 88.4% of children the disease debuted at the age of above 4 y/o. It was associated with a trigger (infections, vaccination, trauma, etc.) in 76.7% of cases. The median (Me) level of antibodies to factor H was 12400 [4187; 22181] AU/ml, which was more than 8 times higher than the normal upper limit. The acute period was characterized by the development of the TMA triad (MAGA, thrombocytopenia, AKI) in 100%, hemorrhagic syndrome (69.8%), arterial hypertension (69.8%), C3 consumption (77.8%) and dysfunction of more than 2 systems (83.7%). Neoliguric form of AKI was diagnosed in 44.2%, cardiac involvement in 65.1%, CNS in 55.8%, GI in 51.2%, pulmonary in 23.3%, and visual organ in 16.3% of cases. CFHR1/CFHR3 deletions were found in 87.8% (36/41) of cases (77.8% homozygous/ 22.2% heterozygous). Relapses were noted in 34.9%. Remission of CFH-Ab-aHUS was achieved in 11.6% of cases using plasma therapy and immunosuppressants, in 88.4% - with complement-blocking therapy (eculizumab). The outcome of the disease was characterized by the development of arterial hypertension (65.1%), CKD (60.5%), hypertrophic (25.6%) and dilated cardiomyopathy (16.3%). Conclusion: thus, in the Russin pediatric population with aHUS, every fifth child is diagnosed with CFH-Ab-aHUS associated with a risk of recurrence in every third child. The most important components of the management of patients with CFH-Ab-aHUS are its timely diagnosis and initiation of pathogenetic therapy (plasma therapy with immunosuppressants/eculizumab).
- 22 February 2024
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 103 (1)
Atypical hemolytic-uremic syndrome associated with antibodies to factor H
Atypical hemolytic-uremic syndrome (aHUS) is an ultra-rare life-threatening disease from the group of thrombotic microangiopathies (TMA) with genetic predisposition factors associated with uncontrolled activation of the alternative complement pathway. In 10% of cases aHUS is acquired and associated with antibodies to factor H (CFH-Ab-aHUS), among which 90% of cases are also determined by a deficiency of plasma proteins related to factor H (CFHR). Information on the course, therapeutic approaches and outcomes of CFH-Ab-aHUS varies Worldwide and is presented by series of clinical observations. The purpose of the research was to determine the patterns of the course and outcomes of CFH-Ab-aHUS to substantiate methods of effective treatment and improve prognosis. Methods used: retro- and prospective analysis of the course and outcomes of CFH-Ab-aHUS in 43 patients in Jan. 2010-Feb. 2022. The sample is continuous. In the development of microangiopathic hemolytic anemia (MAHA), thrombocytopenia and acute kidney injury (AKI), the diagnosis of CFH-Ab-aHUS was established after exclusion of other forms of TMAs and determination of immunoglobulin class G (IgG) in serum against factor H by enzyme-linked immunosorbent assay (ELISA-VIDITEST anti-complement factor H, Czech Republic). In 41 cases molecular genetic study by NGS (next generation sequencing) for aHUS panel and Sanger sequencing were performed. Results: the incidence of CFH-Ab-aHUS was 20.6% among all cases of aHUS. In 88.4% of children the disease debuted at the age of above 4 y/o. It was associated with a trigger (infections, vaccination, trauma, etc.) in 76.7% of cases. The median (Me) level of antibodies to factor H was 12400 [4187; 22181] AU/ml, which was more than 8 times higher than the normal upper limit. The acute period was characterized by the development of the TMA triad (MAGA, thrombocytopenia, AKI) in 100%, hemorrhagic syndrome (69.8%), arterial hypertension (69.8%), C3 consumption (77.8%) and dysfunction of more than 2 systems (83.7%). Neoliguric form of AKI was diagnosed in 44.2%, cardiac involvement in 65.1%, CNS in 55.8%, GI in 51.2%, pulmonary in 23.3%, and visual organ in 16.3% of cases. CFHR1/CFHR3 deletions were found in 87.8% (36/41) of cases (77.8% homozygous/ 22.2% heterozygous). Relapses were noted in 34.9%. Remission of CFH-Ab-aHUS was achieved in 11.6% of cases using plasma therapy and immunosuppressants, in 88.4% - with complement-blocking therapy (eculizumab). The outcome of the disease was characterized by the development of arterial hypertension (65.1%), CKD (60.5%), hypertrophic (25.6%) and dilated cardiomyopathy (16.3%). Conclusion: thus, in the Russin pediatric population with aHUS, every fifth child is diagnosed with CFH-Ab-aHUS associated with a risk of recurrence in every third child. The most important components of the management of patients with CFH-Ab-aHUS are its timely diagnosis and initiation of pathogenetic therapy (plasma therapy with immunosuppressants/eculizumab).
- 1 January 2024
- Published by Russian Dialysis Society in Nephrology and Dialysis
- Vol. 26 (2)
Homocysteine, folic acid and vitamin B12 in children with chronic kidney disease
- 1 January 2024
- Published by Russian Dialysis Society in Nephrology and Dialysis
- Vol. 26 (2)
Homocysteine, folic acid and vitamin B12 in children with chronic kidney disease
- 16 December 2022
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 101 (6)
COMPREHENSIVE APPROACH TO DIAGNOSIS AND THE TREATMENT TACTICS OF ATYPICAL HEMOLYTIC UREMIC SYNDROME ASSOCIATED WITH A MUTATION IN THE CFH GENE: A CLINICAL CASE
The atypical hemolytic uremic syndrome (aHUS) is an ultra-rare disease with a genetically determined dysregulation of the alternative complement pathway, which leads to the development of thrombotic microangiopathy. The application of the targeted therapy in Russia has changed the natural course of the disease since 2012: from death of a patient to achieving a long-term remission of the aHUS. The authors report the clinical case of the aHUS associated with a heterozygous mutation in CFH gene c.2850G>T (p.Gln950His) in a 2 years and 2 months old pediatric patient. The difficulty in diagnosing of the aHUS was the lack of specific laboratory criteria confirming the diagnosis as well as the presence of a diarrheal prodrome at the onset. The diagnosis has been made on the basis of the development of microangiopathic hemolytic anemia, thrombocytopenia, acute kidney injury and the exclusion of other forms of thrombotic microangiopathy. The treatment of the patient in accordance with the clinical guidelines for the management of patients with this nosology proved to be effective and led to a stable remission of the aHUS, which also confirmed the correctness of the diagnosis. The described clinical case observation is of interest to pediatrician physicians and nephrologists. The important factors in the management of such patients are the timely diagnosis of the aHUS along with the initiation of complement-inhibiting Eculizumab therapy.
- 16 December 2022
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 101 (6)
COMPREHENSIVE APPROACH TO DIAGNOSIS AND THE TREATMENT TACTICS OF ATYPICAL HEMOLYTIC UREMIC SYNDROME ASSOCIATED WITH A MUTATION IN THE CFH GENE: A CLINICAL CASE
The atypical hemolytic uremic syndrome (aHUS) is an ultra-rare disease with a genetically determined dysregulation of the alternative complement pathway, which leads to the development of thrombotic microangiopathy. The application of the targeted therapy in Russia has changed the natural course of the disease since 2012: from death of a patient to achieving a long-term remission of the aHUS. The authors report the clinical case of the aHUS associated with a heterozygous mutation in CFH gene c.2850G>T (p.Gln950His) in a 2 years and 2 months old pediatric patient. The difficulty in diagnosing of the aHUS was the lack of specific laboratory criteria confirming the diagnosis as well as the presence of a diarrheal prodrome at the onset. The diagnosis has been made on the basis of the development of microangiopathic hemolytic anemia, thrombocytopenia, acute kidney injury and the exclusion of other forms of thrombotic microangiopathy. The treatment of the patient in accordance with the clinical guidelines for the management of patients with this nosology proved to be effective and led to a stable remission of the aHUS, which also confirmed the correctness of the diagnosis. The described clinical case observation is of interest to pediatrician physicians and nephrologists. The important factors in the management of such patients are the timely diagnosis of the aHUS along with the initiation of complement-inhibiting Eculizumab therapy.
- Open Access
- 21 April 2022
- Published by Paediatrician Publishers LLC in Pediatric pharmacology
- Vol. 19 (2) , 127-152
Modern Approaches to the Management of Children with Atypical Hemolytic Uremic Syndrome
Experts of the Union of Pediatricians of Russia have developed modern guidelines on management of children with atypical hemolytic uremic syndrome (aHUS). aHUS is ultra-rare (orphan) disease with progressive and relapsing course during the life with potentially life-threatening state. This article covers issues of disease etiology, pathogenesis, and classification. Specific attention is paid to the diagnosis, differential diagnosis, and therapy of aHUS according to the evidence-based approaches.
- 21 April 2022
- Published by Paediatrician Publishers LLC in Pediatric pharmacology
- Vol. 19 (2) , 127-152
Open AccessModern Approaches to the Management of Children with Atypical Hemolytic Uremic Syndrome
Experts of the Union of Pediatricians of Russia have developed modern guidelines on management of children with atypical hemolytic uremic syndrome (aHUS). aHUS is ultra-rare (orphan) disease with progressive and relapsing course during the life with potentially life-threatening state. This article covers issues of disease etiology, pathogenesis, and classification. Specific attention is paid to the diagnosis, differential diagnosis, and therapy of aHUS according to the evidence-based approaches.
- 6 August 2021
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 100 (4)
«ADAMTS13 – VON WILLEBRAND FACTOR – PLATELETS» SYSTEM IN ATYPICAL HEMOLYTIC UREMIC SYNDROME IN CHILDREN
Atypical hemolytic uremic syndrome (aHUS) is an orphan disease caused by hyperactivation of the alternative complement pathway. Objective of the study: to assess the state of the «ADAMTS13 – von Willebrand factor (vWF) – platelets» system in children with aHUS. Materials and methods of research: [by the FRET method (fluorescence resonance energy transfer) for the FRETSVWF73 (Peptide Institude, Inc., Japan)] hydrolysis of the fluorescent substrate and ADAMTS13 antigen [by ELISA using TECHNOZYM® ADAMTS13 5450551 ELISA (Technoclone GmbH, Austria)], vWF activity [for platelet agglutination (aggregation) in the presence of ristomycin (NPO Renam reagent kit for the ALAT-230LA-2 aggregometer, Russia)] and vWF antigen [by ELISA using the TECHNOZYM® vWF kit: Ag 5450201 ELISA (Technoclone GmbH , Austria)]. Results: there was a decrease in the activity and concentration of ADAMTS13 in 63% and 62% of patients, respectively. A decrease in vWF activity was noted in 44% of cases, an increase in its concentration – in 54% of children. Thrombocytopenia was diagnosed in 99% of children. Conclusion: the imbalance in the «ADAMTS13 – vWF – platelets» system supports the process of thrombus formation with the development of organ ischemia in aHUS under conditions of endothelial dysfunction. Reduced ADAMTS13 activity predicts the severity of the disease.
- 6 August 2021
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 100 (4)
«ADAMTS13 – VON WILLEBRAND FACTOR – PLATELETS» SYSTEM IN ATYPICAL HEMOLYTIC UREMIC SYNDROME IN CHILDREN
Atypical hemolytic uremic syndrome (aHUS) is an orphan disease caused by hyperactivation of the alternative complement pathway. Objective of the study: to assess the state of the «ADAMTS13 – von Willebrand factor (vWF) – platelets» system in children with aHUS. Materials and methods of research: [by the FRET method (fluorescence resonance energy transfer) for the FRETSVWF73 (Peptide Institude, Inc., Japan)] hydrolysis of the fluorescent substrate and ADAMTS13 antigen [by ELISA using TECHNOZYM® ADAMTS13 5450551 ELISA (Technoclone GmbH, Austria)], vWF activity [for platelet agglutination (aggregation) in the presence of ristomycin (NPO Renam reagent kit for the ALAT-230LA-2 aggregometer, Russia)] and vWF antigen [by ELISA using the TECHNOZYM® vWF kit: Ag 5450201 ELISA (Technoclone GmbH , Austria)]. Results: there was a decrease in the activity and concentration of ADAMTS13 in 63% and 62% of patients, respectively. A decrease in vWF activity was noted in 44% of cases, an increase in its concentration – in 54% of children. Thrombocytopenia was diagnosed in 99% of children. Conclusion: the imbalance in the «ADAMTS13 – vWF – platelets» system supports the process of thrombus formation with the development of organ ischemia in aHUS under conditions of endothelial dysfunction. Reduced ADAMTS13 activity predicts the severity of the disease.
- 14 October 2019
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 98 (5)
THE EXPERIENCE OF USING ELIZARIA FOR ATYPICAL HEMOLYTIC UREMIC SYNDROME
Облако Mail.ru - это ваше персональное надежное хранилище в интернете.
- 14 October 2019
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 98 (5)
THE EXPERIENCE OF USING ELIZARIA FOR ATYPICAL HEMOLYTIC UREMIC SYNDROME
Облако Mail.ru - это ваше персональное надежное хранилище в интернете.
- 10 October 2017
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 96 (5) , 167-176
Thrombotic thrombocytopenic purpura (Moschcowitz disease): literaturereview and clinical observation of the disease in a 7-year-old child
Облако Mail.Ru - это ваше персональное надежное хранилище в интернете. Все нужные файлы всегда под рукой, доступны в любой точке мира с компьютера или смартфона.
- 10 October 2017
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 96 (5) , 167-176
Thrombotic thrombocytopenic purpura (Moschcowitz disease): literaturereview and clinical observation of the disease in a 7-year-old child
Облако Mail.Ru - это ваше персональное надежное хранилище в интернете. Все нужные файлы всегда под рукой, доступны в любой точке мира с компьютера или смартфона.